Grazoprevir/elbasvir combo shows high cure rate for patients with chronic HCV
Embargoed news from Annals of Internal Medicine
2015-04-24
(Press-News.org) Philadelphia, April 24, 2015 -- Once-daily oral grazoprevir/elbasvir combination therapy, taken without interferon or ribavirin for 12 weeks, demonstrated high sustained virologic response rates for treatment-naïve patients with cirrhotic or non-cirrhotic chronic hepatitis C virus (HCV) genotype 1, 4, or 6. These findings suggest that once-daily oral grazoprevir/elbasvir represents a new therapeutic option for chronic HCV infection.
Data from the Phase 3 C-EDGE Treatment-Naïve Trial are being presented for the first time at the 50th annual congress of the European Association for the Study of the Liver in Vienna, Austria, and are published today in Annals of Internal Medicine.
In this randomized, blinded, placebo-controlled, parallel-group trial, 412 mono-infected treatment-naïve patients received either immediate or deferred therapy with grazoprevir/elbasvir. Patients in the immediate treatment group took one fixed-dose combination tablet of grazoprevir/elbasvir once daily at approximately the same time for 12 weeks. Patients in the deferred treatment group followed the same regimen but were given matching placebo. Of the 316 patients in the immediate treatment group, 95 percent had undetectable viral load, or sustained viral response, for 12 consecutive weeks (SVR12) after treatment. SVR12 rates were 92 percent for patients with genotype 1a; 99 percent for genotype 1b; 100 percent for genotype 4; and 80 percent for genotype 6. SVR12 was achieved in 97 percent of cirrhotic patients and 94 percent of non-cirrhotic patients.
INFORMATION:
Note: A link to the paper describing these findings will be live at 9:00 a.m. ET on Friday, April 24 http://www.annals.org/article.aspx?doi=10.7326/M15-0785. For an embargoed PDF of the full paper, please contact Megan Hanks at mhanks@acponline.org. The lead study author, Prof. Stefan Zeuzem, may be contacted by the media directly at zeuzem@em.uni-frankfurt.de.
ELSE PRESS RELEASES FROM THIS DATE:
2015-04-24
Harvard Stem Cell Institute (HSCI) researchers at Massachusetts General Hospital (MGH) have developed an imageable mouse model of brain-metastatic breast cancer and shown the potential of a stem-cell-based therapy to eliminate metastatic cells from the brain and prolong survival. The study published online in the journal Brain also describes a strategy of preventing the potential negative consequences of stem cell therapy.
"Metastatic brain tumors - often from lung, breast or skin cancers - are the most commonly observed tumors within the brain and account for about ...
2015-04-24
April 24, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that a 12-week oral regimen of once-daily single tablet grazoprevir/elbasvir (GZR/EBR) is effective and well-tolerated in treatment-naive (TN) patients infected with chronic hepatitis C virus (HCV) genotypes (GT)-1, -4 or -6, including those with compensated cirrhosis.
Based on preliminary results from 316 GZR/EBR recipients in the immediate treatment arm, 299 patients (95%) achieved a sustained virologic response at 12 weeks (SVR12).
"These initial results ...
2015-04-24
April 24, 2015, Vienna, Austria: A new study presented today at The International Liver Congress™ 2015 has demonstrated that ledipasvir (LDV) in combination with sofosbuvir (SOF) achieves sustained virologic response rates 12 weeks after treatment (SVR12; primary endpoint), of 93% and 95% in patients chronically infected with hepatitis C virus (HCV) genotypes 4 or 5, respectively.
In the study, LDV/SOF was administered in a once-daily, fixed-dose combination tablet for 12 weeks to treatment-naive and treatment-experienced patients with or without cirrhosis. A total ...
2015-04-24
April 24, 2015, Vienna , Austria: Results announced today at The International Liver CongressTM 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV may be an increased risk of cancer.
The aim of the study was to describe the rates of all cancers in the cohort of HCV patients compared to the non-HCV population. Known cancer types associated with hepatitis C include non-Hodgkin's lymphoma, renal and prostate cancers, as well as liver ...
2015-04-24
April 24, 2015, Vienna, Austria: Findings were presented today at The International Liver CongressTM 2015 on a novel therapeutic candidate for a genomically defined subset of hepatocellular carcinoma (HCC) patients with an aberrant fibroblast growth factor receptor 4 (FGFR4) pathway. BLU-554, a small molecule inhibitor of FGFR4, has been identified as a potential treatment option for up to 30% of HCC patients. In preclinical studies, the investigational drug was shown to be potent and 'exquisitely selective' for FGFR4 compared to other kinases targeting the FGFR family. ...
2015-04-24
April 24, 2015, Vienna, Austria: Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD).
Reported today at The International Liver CongressTM 2015, the large study analysed the overall burden of cardiovascular disease and all-cause mortality across the spectrum of NAFLD. The four stages of NAFLD are steatosis (or simple fatty liver), non-alcoholic steatohepatitis ...
2015-04-24
Cincinnati, OH, April 24, 2015 -- Sleep-related deaths are the most common cause of death for infants 1-12 months of age. The American Academy of Pediatrics recommends that infants sleep on their back on a firm mattress, without loose bedding. However, many parents use sitting or carrying devices, such as car seats, swings, or bouncers, as alternative sleeping environments, which could lead to potential injury or death. In a new study scheduled for publication in The Journal of Pediatrics, researchers describe how the improper use of these items can lead to infant deaths.
Erich ...
2015-04-24
Turmeric - the familiar yellow spice common in Indian and Asian cooking - may play a therapeutic role in oral cancers associated with human papillomavirus, according to new research published in ecancermedicalscience.
One of the herb's key active ingredients - an antioxidant called curcumin - appears to have a quelling effect on the activity of human papillomavirus (HPV).
HPV is a virus that promotes the development of cervical and oral cancer. There is no cure, but curcumin may offer a means of future control.
"Turmeric has established antiviral and anti-cancer properties," ...
2015-04-23
SEATTLE - Today, Americans are more likely to be heavy drinkers and binge drinkers than in recent years due in large part to rising rates of drinking among women, according to a new analysis of county-level drinking patterns in the United States.
By contrast, the percentage of people who drink any alcohol has remained relatively unchanged over time, according to the latest research by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington.
Published in the American Journal of Public Health on April 23, the study "Drinking patterns in ...
2015-04-23
SAN FRANCISCO - New ophthalmology research from the University of Miami shows that dry eye - the little understood culprit behind red, watery, gritty feeling eyes - strikes most often in spring, just as airborne allergens are surging. The study marks the first time that researchers have discovered a direct correlation between seasonal allergens and dry eye, with both pollen and dry eye cases reaching a yearly peak in the month of April. The paper was published online today in Ophthalmology, the journal of the American Academy of Ophthalmology.
Dry eye can significantly ...
LAST 30 PRESS RELEASES:
[Press-News.org] Grazoprevir/elbasvir combo shows high cure rate for patients with chronic HCV
Embargoed news from Annals of Internal Medicine
